Atezolizumab (anti-PD-L1) - Primary antibody, INHIBITOR of Programmed cell death 1 ligand 1 inhibitor, INHIBITOR of Programmed cell death 1 ligand 1 inhibitor

CAS: 1380723-44-3 Cat. No.: A411996 PubChem CID: 168009942

GRADE & PURITY Animal Free, ≥95%, See COA

Application

Flow Cytometry

Host species

Human

Reactive species

Human

Isotype

Human IgG1

Conjugation

Unconjugated

Descripción general

A human, Fc optimized, monoclonal antibody directed against the protein ligand PD-L1 (programmed cell death-1 ligand 1), with potential immune checkpoint inhibitory and antineoplastic activities. Atezolizumab binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1) expressed on activated T-cells, which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. In addition, by binding to PD-L1, atezolizumab also prevents binding of this ligand to B7.1 expressed on activated T cells, which further enhances the T-cell-mediated immune response. PD-L1 is overexpressed on many human cancer cell types and on various tumor-infiltrating immune cells. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in increased immune evasion. PD-1, a transmembrane protein, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T cells. The Fc region of atezolizumab is modified in such a way that it does not induce either antibody-dependent cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC).

Specifications

Product Name

Atezolizumab (anti-PD-L1) - Primary antibody, INHIBITOR of Programmed cell death 1 ligand 1 inhibitor

Sinónimos

MPDL3280A

Especificaciones y pureza

Animal Free, ≥95%, See COA

Especies hospedadoras

Human

Conjugación

Unconjugated

Grado

Animal Free

Tipo de acción

INHIBITOR

Mecanismo de acción

INHIBITOR of Programmed cell death 1 ligand 1 inhibitor

Concentración

See COA

CAS

1380723-44-3

Almacenamiento y envío

Condiciones de almacenamiento de almacenamiento

Protected from light,Store at -20°C

Enviado en

Ice chest + Ice pads

Estabilidad y almacenamiento

The diluted protein solution can be stored in cold storage at 2-8 degrees away from light for no more than 2 weeks. Long-term storage is not recommended. Avoid repeated freeze-thaw. The activity of freeze-thaw protein will decrease by about 5% each time.

Imágenes

ELISA: Atezolizumab (anti-PD-L1) (A411996)

Atezolizumab (anti-PD-L1) (A411996) - ELISA

Immobilized Recombinant Human PD-L1 Protein (rp169666) at 1.0 μg/mL can bind Atezolizumab (anti-PD-L1) (A411996) with the EC₅₀ of 8.37 ng/mL.

Flow Cytometry: Atezolizumab (anti-PD-L1) (A411996)

Atezolizumab (anti-PD-L1) (A411996) - Flow Cytometry

Flow Cytometry analysis of MDA-MB-231 cells labelling PD-L1 (red) with Atezolizumab (anti-PD-L1) (A411996) at 0.2 μg/mL for 1 hour at 4°C and detected with AF 488 - conjugated affinipure goat anti - Human IgG. Blue - Human IgG Isotype Control Antibody (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.

Objetivos asociados (humanos)

CD274 Tclin Programmed cell death 1 ligand 1 (0 Activities)

Discover Target: CD274

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

Mecanismos de acción

Referencias

1. Yingchun Zeng, Jingxuan Yang, Ka Wang, Huan Xu, Yue Zheng, Songxin Guo, Jingwen Luo, Sha Liu, Xin Ming, Xue Ying.  (2025)  Multifunctional Polymeric Nanoparticles Codelivering Paclitaxel and Monoclonal Antibodies for Triple Combination Therapy of Colorectal Cancer.  BIOMACROMOLECULES,      [PMID:41246989] [10.1021/acs.biomac.5c01421]